

SUSPECT ADVERSE REACTION REPORT

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last) PRIVACY	1a. COUNTRY COSTA RICA	2. DATE OF BIRTH			2a. AGE 41 Years	3. SEX Female	3a. WEIGHT 79.80 kg	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION <input type="checkbox"/> PATIENT DIED <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALISATION <input type="checkbox"/> INVOLVED PERSISTENT OR SIGNIFICANT DISABILITY OR INCAPACITY <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> CONGENITAL ANOMALY <input type="checkbox"/> OTHER
		Day	Month	Year				Day	Month	Year	
			PRIVACY					11	MAY	2025	

7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)
Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)
she could not sleep [Insomnia]
nausea [Nausea]
vomiting [Vomiting]
had tremors in her hands [Tremor]

Case Description: ***This is an auto generated narrative***

Study ID: 828652-My Healthy Journey

Study description: Trial title: This is a 40 weeks digital patient (Continued on Additional Information Page)

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S) (include generic name) #1) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL {Lot # PP5L468; Exp.Dt. JUN-2026} (Continued on Additional Information Page)		20. DID REACTION ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
15. DAILY DOSE(S) #1) 2.4 mg, qd	16. ROUTE(S) OF ADMINISTRATION #1) Subcutaneous	
17. INDICATION(S) FOR USE #1) for weight loss (Weight control)		21. DID REACTION REAPPEAR AFTER REINTRODUCTION? <input type="checkbox"/> YES <input type="checkbox"/> NO <input type="checkbox"/> NA
18. THERAPY DATES(from/to) #1) 01-MAY-2025 / Unknown	19. THERAPY DURATION #1) Unknown	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)		
23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)		
From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Current Condition	Overweight (Overweight)
	duration not reported.	
Unknown to Ongoing	Current Condition	Cyst (Cyst)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Novo Nordisk A/S Lise Grimmeshave Vandtaarnsvej 114 Soeborg, DK-2860 DENMARK Phone: +45 44448888		26. REMARKS Medically Confirmed: No
	24b. MFR CONTROL NO. 1438117	25b. NAME AND ADDRESS OF REPORTER NAME AND ADDRESS WITHHELD.
24c. DATE RECEIVED BY MANUFACTURER 30-JUN-2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL <input type="checkbox"/> OTHER:	
DATE OF THIS REPORT 23-JUL-2025	25a. REPORT TYPE <input type="checkbox"/> INITIAL <input checked="" type="checkbox"/> FOLLOWUP: 1	

ADDITIONAL INFORMATION**7+13. DESCRIBE REACTION(S) continued**

support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liraglutide 3.0 mg).

Patient's height: 165 cm.

Patient's weight: 79.8 kg.

Patient's BMI: 29.31129480.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "she could not sleep(Sleep difficult)" beginning on 11-MAY-2025 , "nausea(Nausea)" beginning on 11-MAY-2025 , "vomiting(Vomiting)" beginning on 11-MAY-2025 , "had tremors in her hands(Tremor of hands)" beginning on 11-MAY-2025 and concerned a 41 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from 01-MAY-2025 and ongoing for "for weight loss",

Dosage Regimens:

Saxenda: 01-MAY-2025 to Not Reported, Not Reported to Not Reported (Dosage Regimen Ongoing);

Current Condition: Overweight, Cysts, Fibroids in the ovaries, Thyroid cysts.

Treatment medications included - ANTIMETIL(ZINGIBER OFFICINALE).

Batch Numbers:

Saxenda: PP5L468, PP5L468;

Action taken to Saxenda was reported as Dose Decreased.

On 13-MAY-2025 the outcome for the event "she could not sleep(Sleep difficult)" was Recovered.

On 13-MAY-2025 the outcome for the event "nausea(Nausea)" was Recovered.

On 13-MAY-2025 the outcome for the event "vomiting(Vomiting)" was Recovered.

On 13-MAY-2025 the outcome for the event "had tremors in her hands(Tremor of hands)" was Recovered.

Reporter's causality (Saxenda) -

she could not sleep(Sleep difficult) : Unknown

nausea(Nausea) : Unknown

vomiting(Vomiting) : Unknown

had tremors in her hands(Tremor of hands) : Unknown

Company's causality (Saxenda) -

she could not sleep(Sleep difficult) : Possible

nausea(Nausea) : Possible

vomiting(Vomiting) : Possible

had tremors in her hands(Tremor of hands) : Unlikely

Reporter Comment: The patient mentions that the patient is not sure if it was anxiety or due to the dose of Saxenda that was applied; subsequently, after decreasing the dose, the patient no longer experiences the symptoms since the dose was reduced a month and a half ago.

14-19. SUSPECT DRUG(S) continued

14. SUSPECT DRUG(S) (include generic name)	15. DAILY DOSE(S); 16. ROUTE(S) OF ADMIN	17. INDICATION(S) FOR USE	18. THERAPY DATES (from/to); 19. THERAPY DURATION
#1) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL {Lot # PP5L468; Exp.Dt. JUN-2026}; Regimen #2	1.8 mg, qd (Dose decreased); Subcutaneous	for weight loss (Weight control)	Ongoing; Unknown

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
Unknown to Ongoing	Current Condition	Fibroids (Uterine leiomyoma);
Unknown to Ongoing	Current Condition	Thyroid cyst (Thyroid cyst);

ADDITIONAL INFORMATION

23. OTHER RELEVANT HISTORY continued

From/To Dates	Type of History / Notes	Description
---------------	-------------------------	-------------